REPRIEVE试验入组时抗逆转录病毒治疗模式与免疫学特征
REPRIEVE试验纳入7770例40-75岁、正在接受ART且心血管风险低至中度的HIV感染者,总结不同GBD超区域的ART方案及免疫学指标。入组时中位CD4计数620/µL,最常见方案为NRTI+NNRTI(43%);ART方案随地区和入组时间变化,CD4计数与CD4/CD8比值同地区、性别、方案、ART时长及最低CD4计数相关。
要点
- 入组中位CD4为620/µL,中位既往ART时长9.5年。
- 最常见方案为NRTI+NNRTI(43%),其次NRTI+INSTI(25%)与NRTI+PI(19%)。
- ART方案随GBD地区和入组时间变化,提示当地药物可及性与指南差异。
核心结论
- ART使用随地理区域和时间存在明显差异,可能反映当地药物可及性、治疗指南变化及医患偏好。
- CD4计数与CD4/CD8比值分析或为HIV感染者免疫相关性与结局提供线索。
研究设计与样本
- REPRIEVE试验(NCT02344290)入组40-75岁、接受ART且心血管风险低至中度的HIV感染者。
- 共纳入7770例,按GBD超区域总结ART使用,并用校正线性与逻辑回归分析免疫参数与人口学关联。
主要发现
- 中位年龄50岁(IQR 45-55),女性31%,黑人或非裔美国人43%,亚洲人15%。
- BMI>25者56%,目前或既往吸烟者49%。
- 中位CD4计数620/µL(IQR 447-826),中位既往ART时长9.5年(IQR 5.3-14.8)。
- 最常见方案为NRTI+NNRTI(43%)、NRTI+INSTI(25%)、NRTI+PI(19%)。
关键数值与推荐
- 入组CD4计数与CD4/CD8比值同GBD地区、性别、入组方案、ART时长及最低CD4计数相关。
- CD4与CD8计数还同BMI和吸烟状态相关。
临床怎么用
- 评估HIV感染者免疫重建时应结合地区、方案、ART时长与最低CD4计数综合判断。
- 关注吸烟与BMI等可干预因素与CD4、CD8计数的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described. METHODS: The REPRIEVE trial (Randomized Trial to Prevent Vascular Events in HIV) enrolled persons with human immunodeficiency virus (HIV) who were aged 40-75 years, receiving ART, and had low-to-moderate cardiovascular disease risk. ART use was summarized within Global Burden of Disease (GBD) super-regions, with adjusted linear and logistic regression analyses examining associations with immune parameters and key demographics. RESULTS: A total of 7770 participants were enrolled, with a median age of 50 years (interquartile range, 45-55 years); 31% were female, 43% were black or African American, 15% were Asian, 56% had a body mass index >25 (calculated as weight in kilograms divided by height in meters squared), and 49% were current or former smokers. The median CD4 T-cell count was 620/µL (interquartile range, 447-826/ µ L), and the median duration of prior ART use, 9.5 years (5.3-14.8) years. The most common ART regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI) plus nonnucleoside reverse-transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%). Entry ART varied by GBD region, with shifts during the trial enrollment period. In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GBD region, sex, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated with body mass index and smoking status. CONCLUSIONS: There were substantial variations in ART use by geographic region and over time, likely reflecting the local availability of specific medications, changes in treatment guidelines and provider/patient preferences. The analyses of CD4 cell counts and CD4/CD8 ratios may provide valuable insights regarding immune correlates and outcomes in people living with HIV. CLINICAL TRIALS REGISTRATION: NCT02344290.
引用
- Fichtenbaum CJ, Ribaudo HJ, Leon-Cruz J, et al. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2020. PMID: 32645162. doi:10.1093/infdis/jiaa259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。